| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/26/2004 | US20040167092 Medicaments |
| 08/26/2004 | US20040167091 Methods for treating ocular neovascular diseases |
| 08/26/2004 | US20040167089 Immunostimulatory nucleic acid molecules |
| 08/26/2004 | US20040167085 Useful for the treatment of hypercholesterolemia |
| 08/26/2004 | US20040167084 Acne; dermatitis |
| 08/26/2004 | US20040167082 Treatment of rumen acidosis with alpha-amylase inhibitors |
| 08/26/2004 | US20040167081 Method for the prevention and treatment of cachexia and anorexia |
| 08/26/2004 | US20040167080 Osteoporosis; antilipemic agents |
| 08/26/2004 | US20040167079 using 2-deoxyglucose to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, optionally co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy |
| 08/26/2004 | US20040167077 Prevent skin damage; therapy for skin disorders |
| 08/26/2004 | US20040167075 Diagnosis, therapy od Alzheimer's disease; blocking psychological conditions |
| 08/26/2004 | US20040167069 administering a transglutaminase inhibitor, particularly a compound with a 3-halo-dihydroisoxazole moiety or an analog of isatin, to attenuate gluten toxicity |
| 08/26/2004 | US20040167065 human transferases and polynucleotides which identify and encode them; expression vectors, host cells, antibodies, agonists, and antagonists; diagnosing, treating, or preventing disorders associated with aberrant expression of the transferases |
| 08/26/2004 | US20040167062 such as anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia by administering an antimicrobial composition optionally with a probiotic mixture |
| 08/26/2004 | US20040167060 Inhibitor and stimulator of stem cell proliferation and uses thereof |
| 08/26/2004 | US20040167039 containing polyol(s) and a gelling agent; increases in temperature by at least 5 degrees C. upon exposure to moisture and which has a Maximum Energy Release Index of at least 11 mJ/mg.; use for vaginal lubrication, administration of active ingredients and for preventing or treating dysmenorrhea |
| 08/26/2004 | US20040166673 Scaffold-organized clusters and electronic devices made using such clusters |
| 08/26/2004 | US20040166559 Vectors for gene therapy |
| 08/26/2004 | US20040166543 Regulation of cell growth by MUC1 |
| 08/26/2004 | US20040166184 Plant extract; cognition activators |
| 08/26/2004 | US20040166182 Synergistic mixture; enzyme inhibitors; side effect reduction of gastrointestinal disorders |
| 08/26/2004 | US20040166181 Mixture of soybean protein and chromium |
| 08/26/2004 | US20040166180 Use of extracts of ginkgo biloba for preparing a medicament intended to treat sarcopenia |
| 08/26/2004 | US20040166177 Soluble plant extracts; concentrating active materials; mixture of carotenoids, anthocyanins, fatty acid, terpenes, and alkaloids; reducing concentration of sugars |
| 08/26/2004 | US20040166176 Side effect reduction; reducing pain; synergistic mixture containing muscle relaxants; administering prostaglandins |
| 08/26/2004 | US20040166175 Compositions and methods for nutrition supplementation |
| 08/26/2004 | US20040166167 Using vectors; complexing estrogen; drug design |
| 08/26/2004 | US20040166164 Storage stability; uniformity bioavailability ; sustained release; solid phase crystallization; solvent saturation; recovering |
| 08/26/2004 | US20040166162 Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| 08/26/2004 | US20040166160 Modulate release of cyclobenzaprine; multilayer tablet containing hydrated form of cyclobenzaprine; controlling concentration in blood |
| 08/26/2004 | US20040166159 Brain diosrders; controlling dopamine concentration |
| 08/26/2004 | US20040166157 Sustained release; oral administering of drug ; veterinary medicine |
| 08/26/2004 | US20040166156 Direct compression polymer tablet core |
| 08/26/2004 | US20040166148 Sustained release of drug |
| 08/26/2004 | US20040166147 Multilayer; backing layer containing reservoir, covering with aperture , adhesive and lining |
| 08/26/2004 | US20040166142 Products containing polyphenol(s) and L-arginine |
| 08/26/2004 | US20040166137 Prevention membrane fusion, transmission of virus; respiratory syncytial virus |
| 08/26/2004 | US20040166127 Skin preparation |
| 08/26/2004 | US20040166109 Modulator polypeptide for regulation of intracellular endocytosis of amyloid precursor proteins; diagnosis and treatment of neurodegenerative disorders |
| 08/26/2004 | US20040166092 Use of viral vectors and charged molecules for gene therapy |
| 08/26/2004 | US20040166090 Antitumor agents; induction apoptosis |
| 08/26/2004 | US20040166088 Polymeric precursors of non-absorbable, in situ-forming hydrogels and applications thereof |
| 08/26/2004 | US20040166079 N-Lauroyl amino acid composition for slimming the human body |
| 08/26/2004 | US20040166067 Pharmaceutical compositions |
| 08/26/2004 | US20040166066 Compositions to reduce congestion and methods for application thereof to the nasal membrane |
| 08/26/2004 | US20040166065 anticholinergics in the treatment of respiratory complaints, particularly in the treatment of inflammatory and/or obstructive diseases of the respiratory tract, particularly for treating asthma or COPD (chronic obstructive pulmonary disease). |
| 08/26/2004 | US20040163654 Inhibition of chronic tissue transplant rejection |
| 08/26/2004 | DE4420690B4 Verwendung von Chaulmoograölen auf dem Gebiet der Kosmetik und Pharmazie, insbesondere der Dermatologie zum Abgleich der Pigmentierung der Haut Use of Chaulmoograölen in the field of cosmetics and pharmaceuticals, especially dermatology to balance skin pigmentation |
| 08/26/2004 | DE19829516B4 Wasserlöslicher nativer Trockenextrakt aus Gingko biloba mit hohem Gehalt an Terpenoiden und Flavonglykosiden Water soluble native dry extract of Ginkgo biloba with a high content of flavone glycosides and terpenoids |
| 08/26/2004 | DE10306203A1 New 2-heteroaryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or pain are NMDA antagonists |
| 08/26/2004 | DE10306202A1 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist |
| 08/26/2004 | DE10306181A1 Stent releasing drug selectively inhibiting proliferation of smooth muscle cells relative to smooth coronary endothelial cells, to prevent restenosis without causing adverse after-effects |
| 08/26/2004 | DE10306179A1 Composition useful for preventing stroke comprises dipyridamole or its salt, acetyl salicylic acid and an angiotensin II antagonist |
| 08/26/2004 | DE10305811A1 Surgical implant, preferably in net form, comprises basic structure containing anabolic steroid and corticosteroid to accelerate healing and reduce scar contraction |
| 08/26/2004 | DE10305661A1 Composition used for controlled, colon-specific release of alpha-lipoic acid or derivative, for treatment of inflammatory colon diseases, containing cationogenic polymer, organic acid and polymeric auxiliary |
| 08/26/2004 | DE10305319A1 Treating bacterial infections of respiratory organs comprises local administration of ciprofloxacin, enrofloxacin or their sparingly soluble salts in solid form |
| 08/26/2004 | DE10305213A1 Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms Use of a new polymorphism in the gene hsgk1 for diagnosing hypertension and use of the sgk gene family for the diagnosis and therapy of the Long-Q / T syndrome |
| 08/26/2004 | DE10305138A1 Composition, useful for the prophylaxis/treatment of hepatitis C virus infection and/or associated diseases, comprises an agent e.g. selenium, all trans retinoic acid or 9-cis retinoic acid |
| 08/26/2004 | DE10305137A1 Transdermale therapeutische Abgabesysteme mit einem Butenolid Transdermal therapeutic delivery systems with a butenolide |
| 08/26/2004 | DE10305070A1 Use of sodium-hydrogen ion antiporter 1 inhibitors e.g. N-(4,5-bis-methanesulfonyl-2-methyl-2-methyl-benzoyl)-guanidine, used at doses causing only partial inhibition, e.g. for treating arrhythmia or angina |
| 08/26/2004 | DE10303229A1 α-Liponsäure, Ambroxol und/oder Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen α-lipoic acid, ambroxol and / or inhibitors of the angiotensin converting enzyme (ACE) comprehensive drug preparation and their use for the treatment of neurodegenerative diseases |
| 08/26/2004 | DE10247271A1 Use of new and known 7-(methyl or trifluoromethyl)-imidazo-(1,2-a)-pyridines as nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, neurodegenerative diseases, inflammatory pain, diabetes or cancer |
| 08/26/2004 | DE102004003224A1 Transdermal patch for administering a drug at a temperature above skin temperature comprises a drug-impermeable backing layer, a drug-containing silicone-based matrix layer, a release liner and a heating element |
| 08/26/2004 | CA2791225A1 Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| 08/26/2004 | CA2785954A1 Crystalline forms of pitavastatin calcium |
| 08/26/2004 | CA2517491E Injectable liquid formulation of paracetamol |
| 08/26/2004 | CA2516344A1 Tra16 a tr4/tr2 repressor |
| 08/26/2004 | CA2516265A1 Use of r-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain |
| 08/26/2004 | CA2516254A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 08/26/2004 | CA2515941A1 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention |
| 08/26/2004 | CA2515838A1 Piperidine-benzenesulfonamide derivatives |
| 08/26/2004 | CA2515761A1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 08/26/2004 | CA2515728A1 Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives |
| 08/26/2004 | CA2515676A1 Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders |
| 08/26/2004 | CA2515658A1 Medicinal composition |
| 08/26/2004 | CA2515638A1 Novel bicyclic compounds and compositions |
| 08/26/2004 | CA2515631A1 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
| 08/26/2004 | CA2515544A1 Compounds for the treatment of viral infection |
| 08/26/2004 | CA2515534A1 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 08/26/2004 | CA2515530A1 New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action |
| 08/26/2004 | CA2515424A1 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions |
| 08/26/2004 | CA2515418A1 Hydroxy-tetrahydro-naphthalenylurea derivatives |
| 08/26/2004 | CA2515407A1 Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form |
| 08/26/2004 | CA2515400A1 Method for treating hypothyroidism |
| 08/26/2004 | CA2515397A1 New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies |
| 08/26/2004 | CA2515395A1 New pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins |
| 08/26/2004 | CA2515394A1 Enantiomeric amphetamine compositions for the treatment of adhd |
| 08/26/2004 | CA2515368A1 Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| 08/26/2004 | CA2515218A1 Process for preparing pyrrolotriazine kinase inhibitors |
| 08/26/2004 | CA2515216A1 Macrocyclic hepatitis c serine protease inhibitors |
| 08/26/2004 | CA2515215A1 Vanilloid receptor ligands and their use in treatments |
| 08/26/2004 | CA2515208A1 Nell peptide expression systems and bone formation activity of nell peptide |
| 08/26/2004 | CA2515190A1 Triazolo-pyridines as anti-inflammatory compounds |
| 08/26/2004 | CA2515130A1 Method of stabilizing lansoprazole |
| 08/26/2004 | CA2515083A1 Topical delivery of cosmetic agents |
| 08/26/2004 | CA2514997A1 Use of il-6 antagonists in combination with steroids to enhance apoptosis |
| 08/26/2004 | CA2514912A1 Rnai targeting of viruses |
| 08/26/2004 | CA2514794A1 Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries |
| 08/26/2004 | CA2514720A1 Coated particles and pharmaceutical dosage forms |
| 08/26/2004 | CA2514650A1 Use of edible acids in fast-dispersing pharmaceutical solid dosage forms |